PULS Cardiac Test Performance Data Measuring Endothelial Injury to Predict Acute Coronary Syndrome to be presented at 2017 American Heart Association Scientific Sessions
Leading cardiologist, Dr. Americo Simonini, will demonstrate how immune response biomarkers predict ACS and improve patient care
May 4th 2017, Minneapolis, MN - Dr. Americo Simonini, Cardiologist at Cedars Sinai and fellow of the American College of Cardiology, will conduct a scientific presentation on immune response biomarkers that effectively measure the continuous process of endothelial injury to predict ACS, or unstable cardiac lesion rupture at the 2017 AHA ATVB|PVD Scientific Sessions.
The abstract analyzes data collected from a range of cardiology practices across the United States, comparing the patients initial risk status as determined by a modified Framingham Risk Score (mFRS), to a cardiac score provided by the PULS Cardiac Test, referred to as a CADPA (Coronary Artery Disease Predictive Algorithm). Conclusions from the abstract suggest that this methodology marks a significant improvement over current methods in identifying subclinical coronary artery disease.
“We see this data as foundational blocks that help physicians redefine the standard of care,” commented Dr. Simonini. “Our goal is to improve identification of asymptomatic ‘vulnerable patients’ at risk of experiencing a cardiac event, but who may be missed by current methods. The data on the PULS Cardiac Test shows significant re-classification across all ages and races, representing an exciting step on the path to more effective, affordable prevention on a global level.”
The presentation follows the recent case study published by the American College of Cardiology online that highlights the clinical utility of the PULS Cardiac Test in detecting subclinical coronary artery disease in a 46 year-old male, later confirmed by CCTA.
Dr. Simonini co-authored the presentation with Dr. Douglas Harrington, Clinical Professor at USC Keck School of Medicine and Co-Founder of the PULS Cardiac Test. The presentation entitled “Novel biomarker algorithmic panel measuring permutations of immune response to cardiac endothelial injury and global risk factors identifies patients at risk of acute coronary syndrome (ACS)” will take place on Thursday, May 4th, 2017 from 5:00-8:00pm.
The annual meeting ATVB|PVD 2017 Scientific Sessions includes diverse disciplines within the arteriosclerosis, thrombosis, vascular biology, peripheral vascular disease, vascular surgery, and functional genomics research communities that allow investigators to explore areas of cross-disciplinary interests.
About the PULS Cardiac Test
The PULS Cardiac Test, developed by GD Biosciences, is a simple blood test that identifies individuals with active, yet undetected subclinical Coronary Heart Disease (CHD), who are at risk of experiencing a Heart Attack, and for whom early intervention can help. The test measures protein biomarkers of the body’s immune response to continuous endothelial injury leading to the formation and progression unstable cardiac lesions – the #1 cause of Heart Attacks. The PULS Cardiac Test has been highlighted by leading cardiology institutions, is now available in over 7 countries worldwide, and recently received the 1st Place Award for Innovation in Healthcare.